ginsenoside a 1

Ginsenoside Rs1, extracted from the root of Panax ginseng [1], is a chemical compound with potential pharmacological properties.

Ginsenoside Rs1 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rs1. Ginsenoside Rs1, extracted from the root of Panax ginseng [1], is a chemical compound with potential pharmacological properties.

3-Acetyl-ginsenoside F1 is a useful organic compound for research related to life sciences and the catalog number is TN6448.

Pseudoginsenoside F11 (Ginsenoside A1) is a component of Panax quinquefolium (American ginseng) which main pharmacological activities are positive inotropic effect on isolated heart function, good therapeutic effect on myocardial ischemia, and good protective effect on cardio-cerebrovascular system and nervous system.

Ginsenoside Rg1 (Panaxoside Rg1) is a class of steroid glycosides, and triterpene saponins found exclusively in the plant genus Panax (ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.

Ginsenoside Rh1 (Sanchinoside B2) , one of the main constituents of Panax ginseng, exhibits anti-inflammatory effect.

Ginsenoside Ro (Chikusetsusaponin V) can reduce TXA2 production, weakly reduce COX-1 and TXAS activities, and has antiplatelet effects as a Ca2+ antagonist with an IC50 of 155 μM.

Zingibroside R1 (Ginsenoside Z-R1) has anti-HIV-1 activity.

1. Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. 2. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. 3. Ginsenoside Rg5 can ameliorate lung inflammation possib

1. Ginsenoside Rk3 and Rh4 could have a role in treating inflammatory diseases. 2. Ginsenoside Rk3 is often used as a major ingredient of the compound preparation for ischemic heart diseases.

Ginsenoside Ra6 is a rare and newly identified protopanaxadiol-type triterpene saponin isolated from Asian ginseng (Panax ginseng), distinguished by unique butenoyl and acetyl sugar modifications on the dammarane core structure that reduce polarity and define it as a Ra-type variant, making it a valuable compound for advanced pharmacological, metabolic, and natural product research investigations.

Ginsenoside Rg2 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rg2. Ginsenoside Rg2 (Chikusetsusaponin I) is one of the major active components of ginseng, act as an NF-κB inhibitor.

Zingibroside R1 (Standard) is a reference standard for research and analysis in studies involving Zingibroside R1. Zingibroside R1 (Ginsenoside Z-R1) has anti-HIV-1 activity.

Ginsenoside F3 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside F3. Ginsenoside-F3 has immunoenhancing activity by regulating production and gene expression of type 1, type 2 cytokines in murine spleen cells. Ginsenoside-F3 enhances the NF-kappaB DNA binding activity induced by ConA in murine spleen cells (10 μM).

Ginsenoside Ra6 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Ra6. Ginsenoside Ra6 (Ginsenoside IV), a panaxadiol-type ginsenoside, is isolated from the roots of ginseng [1].

Ginsenoside Rg5 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rg5. 1. Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. 2. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. 3. Ginsenoside Rg5 can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. 4. Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature. 5. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.

Ginsenoside Rh4 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rh4. 1. Ginsenoside Rh4 could be safely used as adjuvant with low or non-haemolytic effect. 2. Ginsenoside Rh4 has cytotoxic activity and its aglycone against cancer cell lines.

Ginsenoside Ro (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Ro. Ginsenoside Ro (Chikusetsusaponin V) can reduce TXA2 production, weakly reduce COX-1 and TXAS activities, and has antiplatelet effects as a Ca2+ antagonist with an IC50 of 155 μM.